

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

**Highly Specialised Technologies Evaluation
Odevixibat for progressive familial intrahepatic cholestasis ID1570**

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Albireo (obevoxibat) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Addenbrookes Liver Transplant Association • British Liver Trust • Children's Liver Disease Foundation • Contact • Genetic Alliance UK • Findacure • Liver4Life • Muslim Council of Great Britain • National Children's Bureau • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for the Study of the Liver • British Liver Nurses Forum • British Society of Gastroenterology • British Society of Paediatric Gastroenterology, Hepatology and Nutrition • British Transplantation Society • Neonatal and Paediatric Pharmacists Group • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Physicians • Royal Pharmaceutical Society • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • National Services Division (specialised services in Scotland) • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Foundation for Liver Research • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • UK National Screening Committee <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • Addenbrooke's Paediatric Gastrohepatology • Birmingham Children's Hospital NHS Foundation Trust Paediatric Gastrohepatology • King's College Hospital NHS Foundation Trust • Leeds Teaching Hospitals NHS Trust • Department of Endocrinology, University Hospital Birmingham Foundation Trust • Great Ormond Street Paediatric Gastrohepatology • Royal Free Paediatric Gastrohepatology • Welsh Government 	<ul style="list-style-type: none"> • Public Health Wales

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the provisional stakeholder list and which organisations, we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.